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background: Clinicians routinely prescribe proton-pump inhibitors (PPIs) to reduce gastrointestinal complications among patients receiving dual 
antiplatelet therapy with aspirin and clopidogrel. Concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel.
Methods: We evaluated patients enrolled in the multinational prospective Patterns of Non-Adherence to Antiplatelet Regimens in Stented Patients 
(PARIS) registry who were discharged on aspirin and clopidogrel (n=4635), and compared outcomes by presence or absence of discharge PPI 
therapy. We evaluated the association of PPI use with major ischemic outcomes - cardiac death, myocardial infarction, definite/probable stent 
thrombosis and bleeding outcomes (BARC ≥ 2).
results: Of the 4635 patients, 1062 (23%) were discharged on PPIs. Patients receiving PPI were more often female, older, suffered a prior MI, and 
less likely to receive 2nd generation DES. Over 2 years, major cardiovascular event rates were not significantly higher among those with vs. without 
discharge PPI therapy [7.8% vs. 6.3%, adjusted HR 1.23 (0.94-1.59) p=0.13]. The BARC ≥ 2 bleeding rates were 8.4% with PPI therapy and 8.6% 
without [adjusted HR= 0.88 (0.73-1.06) p=0.17] (Fig). These results were consistent across different PPI agents.
conclusions: Among patients receiving aspirin and clopidogrel, prophylactic use of PPI was not associated with a higher risk for ischemic events. 
Bleeding rates were also not appreciably different according to PPI use.
